Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis

Cryptogenic fibrosing alveolitis (CFA), synonymous with idiopathic pulmonary fibrosis (IPF), remains a life-threatening disease: 50% of patients die within 5 yrs. Historically, many diseases that are now considered to be quite distinct have been "labelled" as CFA. More recently, high-resol...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The European respiratory journal 2001-09, Vol.18 (Supplement 32), p.43S-55S
Hauptverfasser: du Bois, R.M, Wells, A.U
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 55S
container_issue Supplement 32
container_start_page 43S
container_title The European respiratory journal
container_volume 18
creator du Bois, R.M
Wells, A.U
description Cryptogenic fibrosing alveolitis (CFA), synonymous with idiopathic pulmonary fibrosis (IPF), remains a life-threatening disease: 50% of patients die within 5 yrs. Historically, many diseases that are now considered to be quite distinct have been "labelled" as CFA. More recently, high-resolution computed tomography and new appreciation of the histopathological patterns of idiopathic interstitial pneumonias have enabled disease variants to be defined according to their different responses to therapy and survival. CFA is believed to be induced by an external agent, although it is not clear whether CFA represents the final common outcome of numerous pathogenetic mechanisms or has a single cause. In addition, there are currently no prospective double-blind, placebo-controlled trials of treatment showing superiority of one drug regimen over another. This review attempts to dissect the different patterns of cryptogenic fibrosing alveolitis, illustrate the major features of each, and refine the clinico-radiological-pathological descriptors that together define cryptogenic fibrosing alveolitis as it is understood today.
doi_str_mv 10.1183/09031936.01.18s320043
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1183_09031936_01_18s320043</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>11816824</sourcerecordid><originalsourceid>FETCH-LOGICAL-c222t-ada105ff5545b2a06feaaac5f43672732a88221a3933611dfa1887ae86b3de6f3</originalsourceid><addsrcrecordid>eNpFkMtOwzAQRS0EoqXwCaB-AGk9nsR1Nkio4iVVYgGsrUlit66SxrJTUP-eVG1hNYs5987oMHYLfAKgcMpzjpCjnHCYgIooOE_xjA0B8zxBzvGcDfdMsocG7CrGNecgU4RLNugbQCqRDtnDPOx81y7NxpVj64rQRrdZjqn-Nm3tOhenrnKtp27V7_22btoNhd2JjNfswlIdzc1xjtjX89Pn_DVZvL-8zR8XSSmE6BKqCHhmbZalWSGIS2uIqMxsinImZihIKSGAMEeUAJUlUGpGRskCKyMtjlh26C37szEYq31wTf-JBq73PvTJh-ag_3z0ubtDzm-LxlT_qaOAHrg_ACu3XP24YHRsqK57HLQJa1AahY5b72ud4gf-ApfmbE0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis</title><source>MEDLINE</source><source>EZB Electronic Journals Library</source><creator>du Bois, R.M ; Wells, A.U</creator><creatorcontrib>du Bois, R.M ; Wells, A.U</creatorcontrib><description>Cryptogenic fibrosing alveolitis (CFA), synonymous with idiopathic pulmonary fibrosis (IPF), remains a life-threatening disease: 50% of patients die within 5 yrs. Historically, many diseases that are now considered to be quite distinct have been "labelled" as CFA. More recently, high-resolution computed tomography and new appreciation of the histopathological patterns of idiopathic interstitial pneumonias have enabled disease variants to be defined according to their different responses to therapy and survival. CFA is believed to be induced by an external agent, although it is not clear whether CFA represents the final common outcome of numerous pathogenetic mechanisms or has a single cause. In addition, there are currently no prospective double-blind, placebo-controlled trials of treatment showing superiority of one drug regimen over another. This review attempts to dissect the different patterns of cryptogenic fibrosing alveolitis, illustrate the major features of each, and refine the clinico-radiological-pathological descriptors that together define cryptogenic fibrosing alveolitis as it is understood today.</description><identifier>ISSN: 0903-1936</identifier><identifier>ISSN: 0904-1850</identifier><identifier>EISSN: 1399-3003</identifier><identifier>DOI: 10.1183/09031936.01.18s320043</identifier><identifier>PMID: 11816824</identifier><language>eng</language><publisher>England: Eur Respiratory Soc</publisher><subject>Humans ; Prognosis ; Pulmonary Fibrosis - diagnosis ; Pulmonary Fibrosis - etiology ; Pulmonary Fibrosis - pathology ; Pulmonary Fibrosis - therapy ; United Kingdom - epidemiology</subject><ispartof>The European respiratory journal, 2001-09, Vol.18 (Supplement 32), p.43S-55S</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c222t-ada105ff5545b2a06feaaac5f43672732a88221a3933611dfa1887ae86b3de6f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11816824$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>du Bois, R.M</creatorcontrib><creatorcontrib>Wells, A.U</creatorcontrib><title>Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis</title><title>The European respiratory journal</title><addtitle>Eur Respir J Suppl</addtitle><description>Cryptogenic fibrosing alveolitis (CFA), synonymous with idiopathic pulmonary fibrosis (IPF), remains a life-threatening disease: 50% of patients die within 5 yrs. Historically, many diseases that are now considered to be quite distinct have been "labelled" as CFA. More recently, high-resolution computed tomography and new appreciation of the histopathological patterns of idiopathic interstitial pneumonias have enabled disease variants to be defined according to their different responses to therapy and survival. CFA is believed to be induced by an external agent, although it is not clear whether CFA represents the final common outcome of numerous pathogenetic mechanisms or has a single cause. In addition, there are currently no prospective double-blind, placebo-controlled trials of treatment showing superiority of one drug regimen over another. This review attempts to dissect the different patterns of cryptogenic fibrosing alveolitis, illustrate the major features of each, and refine the clinico-radiological-pathological descriptors that together define cryptogenic fibrosing alveolitis as it is understood today.</description><subject>Humans</subject><subject>Prognosis</subject><subject>Pulmonary Fibrosis - diagnosis</subject><subject>Pulmonary Fibrosis - etiology</subject><subject>Pulmonary Fibrosis - pathology</subject><subject>Pulmonary Fibrosis - therapy</subject><subject>United Kingdom - epidemiology</subject><issn>0903-1936</issn><issn>0904-1850</issn><issn>1399-3003</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkMtOwzAQRS0EoqXwCaB-AGk9nsR1Nkio4iVVYgGsrUlit66SxrJTUP-eVG1hNYs5987oMHYLfAKgcMpzjpCjnHCYgIooOE_xjA0B8zxBzvGcDfdMsocG7CrGNecgU4RLNugbQCqRDtnDPOx81y7NxpVj64rQRrdZjqn-Nm3tOhenrnKtp27V7_22btoNhd2JjNfswlIdzc1xjtjX89Pn_DVZvL-8zR8XSSmE6BKqCHhmbZalWSGIS2uIqMxsinImZihIKSGAMEeUAJUlUGpGRskCKyMtjlh26C37szEYq31wTf-JBq73PvTJh-ag_3z0ubtDzm-LxlT_qaOAHrg_ACu3XP24YHRsqK57HLQJa1AahY5b72ud4gf-ApfmbE0</recordid><startdate>20010901</startdate><enddate>20010901</enddate><creator>du Bois, R.M</creator><creator>Wells, A.U</creator><general>Eur Respiratory Soc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20010901</creationdate><title>Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis</title><author>du Bois, R.M ; Wells, A.U</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c222t-ada105ff5545b2a06feaaac5f43672732a88221a3933611dfa1887ae86b3de6f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Humans</topic><topic>Prognosis</topic><topic>Pulmonary Fibrosis - diagnosis</topic><topic>Pulmonary Fibrosis - etiology</topic><topic>Pulmonary Fibrosis - pathology</topic><topic>Pulmonary Fibrosis - therapy</topic><topic>United Kingdom - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>du Bois, R.M</creatorcontrib><creatorcontrib>Wells, A.U</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>The European respiratory journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>du Bois, R.M</au><au>Wells, A.U</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis</atitle><jtitle>The European respiratory journal</jtitle><addtitle>Eur Respir J Suppl</addtitle><date>2001-09-01</date><risdate>2001</risdate><volume>18</volume><issue>Supplement 32</issue><spage>43S</spage><epage>55S</epage><pages>43S-55S</pages><issn>0903-1936</issn><issn>0904-1850</issn><eissn>1399-3003</eissn><abstract>Cryptogenic fibrosing alveolitis (CFA), synonymous with idiopathic pulmonary fibrosis (IPF), remains a life-threatening disease: 50% of patients die within 5 yrs. Historically, many diseases that are now considered to be quite distinct have been "labelled" as CFA. More recently, high-resolution computed tomography and new appreciation of the histopathological patterns of idiopathic interstitial pneumonias have enabled disease variants to be defined according to their different responses to therapy and survival. CFA is believed to be induced by an external agent, although it is not clear whether CFA represents the final common outcome of numerous pathogenetic mechanisms or has a single cause. In addition, there are currently no prospective double-blind, placebo-controlled trials of treatment showing superiority of one drug regimen over another. This review attempts to dissect the different patterns of cryptogenic fibrosing alveolitis, illustrate the major features of each, and refine the clinico-radiological-pathological descriptors that together define cryptogenic fibrosing alveolitis as it is understood today.</abstract><cop>England</cop><pub>Eur Respiratory Soc</pub><pmid>11816824</pmid><doi>10.1183/09031936.01.18s320043</doi></addata></record>
fulltext fulltext
identifier ISSN: 0903-1936
ispartof The European respiratory journal, 2001-09, Vol.18 (Supplement 32), p.43S-55S
issn 0903-1936
0904-1850
1399-3003
language eng
recordid cdi_crossref_primary_10_1183_09031936_01_18s320043
source MEDLINE; EZB Electronic Journals Library
subjects Humans
Prognosis
Pulmonary Fibrosis - diagnosis
Pulmonary Fibrosis - etiology
Pulmonary Fibrosis - pathology
Pulmonary Fibrosis - therapy
United Kingdom - epidemiology
title Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T06%3A14%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cryptogenic%20fibrosing%20alveolitis/idiopathic%20pulmonary%20fibrosis&rft.jtitle=The%20European%20respiratory%20journal&rft.au=du%20Bois,%20R.M&rft.date=2001-09-01&rft.volume=18&rft.issue=Supplement%2032&rft.spage=43S&rft.epage=55S&rft.pages=43S-55S&rft.issn=0903-1936&rft.eissn=1399-3003&rft_id=info:doi/10.1183/09031936.01.18s320043&rft_dat=%3Cpubmed_cross%3E11816824%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/11816824&rfr_iscdi=true